Lv42
462 积分 2021-11-25 加入
Reflections on 10 years of the FDA's breakthrough therapy designation
1小时前
已完结
Clinical Trial Evidence Supporting FDA Approval of Drugs Granted Breakthrough Therapy Designation
2小时前
已关闭
Synthetic studies towards the mannolides: Construction of the bowl-shaped B/C/D ring system
20小时前
已完结
Design and Evaluation of a Low Hydrogen Bond Donor Count Fragment Screening Set to Aid Hit Generation of PROTACs Intended for Oral Delivery
21小时前
已完结
Discovery of an orally bioavailable, CNS active pan-mutant RET kinase heterobifunctional degrader
5天前
已完结
Identification of a Potent and Selective CDK9 Degrader as a Targeted Therapeutic Option for the Treatment of Small-Cell Lung Cancer
6天前
已完结
Discovery of the First Clinical Protein Degrader for the Treatment of Autoimmune Indications: Orally Bioavailable and Selective IRAK4 Degrader KT-474
6天前
已完结
Discovery and Characterization of PVTX-321 as a Potent and Orally Bioavailable Estrogen Receptor Degrader for ER+/HER2– Breast Cancer
6天前
已完结
Design and Synthesis of Novel Cereblon Binders for Use in Targeted Protein Degradation
7天前
已完结
Evaluation of Cereblon-Directing Warheads for the Development of Orally Bioavailable PROTACs
7天前
已完结
皖公网安备34019202002308
